{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T10:46:56Z","timestamp":1764499616559,"version":"3.46.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,30]]},"DOI":"10.7759\/cureus.98135","type":"journal-article","created":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T10:46:11Z","timestamp":1764499571000},"source":"Crossref","is-referenced-by-count":0,"title":["Bridging Haemato-Oncology and Critical Care: Survival and Functional Outcomes From a Portuguese Central Hospital"],"prefix":"10.7759","author":[{"given":"Diana","family":"Martins Fernandes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Airosa Pardal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Ferraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Queir\u00f3s Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Henriques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Valois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcia","family":"Rocha Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00facia","family":"Meireles Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiomar","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Couto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Artur","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuno","family":"Pr\u00edncipe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medin.2018.01.008","article-title":"Intensive care in cancer patients in the age of immunotherapy and molecular therapies: commitment of the SEOM-SEMICYUC","volume":"42","author":"Carmona-Bayonas A","year":"2018","unstructured":"Carmona-Bayonas A, Gordo F, Beato C, Casta\u00f1o P\u00e9rez J, Jim\u00e9nez-Fonseca P, Virizuela Echaburu J, Garnacho-Montero J. Intensive care in cancer patients in the age of immunotherapy and molecular therapies: commitment of the SEOM-SEMICYUC. Med Intensiva (Engl Ed). 2018, 42:363-369. 10.1016\/j.medin.2018.01.008","journal-title":"Med Intensiva (Engl Ed)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky F","year":"2017","unstructured":"Kroschinsky F, St\u00f6lzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, Schellongowski P. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017, 21:89. 10.1186\/s13054-017-1678-1","journal-title":"Crit Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/frhem.2023.1127322","article-title":"Predicting outcomes of hematological malignancy patients admitted to critical care","volume":"2","author":"Tridente A","year":"2023","unstructured":"Tridente A, Dempsey NC, Khalifa M, et al.. Predicting outcomes of hematological malignancy patients admitted to critical care. Front Hematol. 2023, 2:1127322. 10.3389\/frhem.2023.1127322","journal-title":"Front Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/cc6921","article-title":"Resource use and outcome in critically ill patients with hematological malignancy: a retrospective cohort study","volume":"12","author":"Merz TM","year":"2008","unstructured":"Merz TM, Sch\u00e4r P, B\u00fchlmann M, Takala J, Rothen HU. Resource use and outcome in critically ill patients with hematological malignancy: a retrospective cohort study. Crit Care. 2008, 12:R75. 10.1186\/cc6921","journal-title":"Crit Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3336","article-title":"Time-limited trials of intensive care for critically ill patients with cancer: How long is long enough?","volume":"2","author":"Shrime MG","year":"2016","unstructured":"Shrime MG, Ferket BS, Scott DJ, et al.. Time-limited trials of intensive care for critically ill patients with cancer: How long is long enough?. JAMA Oncol. 2016, 2:76-83. 10.1001\/jamaoncol.2015.3336","journal-title":"JAMA Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5935\/2965-2774.20230405-en","article-title":"High-value care for critically ill oncohematological patients: what do we know thus far?","volume":"35","author":"Atallah FC","year":"2023","unstructured":"Atallah FC, Caruso P, Nassar AP Junior, Torelly AP, Amendola CP, Salluh JI, Romano TG. High-value care for critically ill oncohematological patients: what do we know thus far?. Crit Care Sci. 2023, 35:84-96. 10.5935\/2965-2774.20230405-en","journal-title":"Crit Care Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden PJ","year":"2022","unstructured":"Hayden PJ, Roddie C, Bader P, et al.. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022, 33:259-275. 10.1016\/j.annonc.2021.12.003","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200810-1614OC","article-title":"Prevalence and factors of intensive care unit conflicts: the conflicus study","volume":"180","author":"Azoulay E","year":"2009","unstructured":"Azoulay E, Timsit JF, Sprung CL, et al.. Prevalence and factors of intensive care unit conflicts: the conflicus study. Am J Respir Crit Care Med. 2009, 180:853-860. 10.1164\/rccm.200810-1614OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref9","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken MM","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982, 5:649-655.","journal-title":"Am J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer M","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, et al.. The Third International Consensus Definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016, 315:801-810. 10.1001\/jama.2016.0287","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner H","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al.. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022, 140:1345-1377. 10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies","volume":"12","author":"von Elm E","year":"2014","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014, 12:1495-1499. 10.1016\/j.ijsu.2014.07.013","journal-title":"Int J Surg"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6628.1025","article-title":"Prognosis of patients receiving intensive care for lifethreatening medical complications of haematological malignancy","volume":"296","author":"Lloyd-Thomas AR","year":"1988","unstructured":"Lloyd-Thomas AR, Wright I, Lister TA, Hinds CJ. Prognosis of patients receiving intensive care for lifethreatening medical complications of haematological malignancy. Br Med J (Clin Res Ed). 1988, 296:1025-1029. 10.1136\/bmj.296.6628.1025","journal-title":"Br Med J (Clin Res Ed)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.2365","article-title":"Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en r\u00e9animation onco-h\u00e9matologique study","volume":"31","author":"Azoulay E","year":"2013","unstructured":"Azoulay E, Mokart D, P\u00e8ne F, et al.. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en r\u00e9animation onco-h\u00e9matologique study. J Clin Oncol. 2013, 31:2810-2818. 10.1200\/JCO.2012.47.2365","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-3714-z","article-title":"The prognostic factors for patients with hematological malignancies admitted to the intensive care unit","volume":"5","author":"Cheng Q","year":"2016","unstructured":"Cheng Q, Tang Y, Yang Q, Wang E, Liu J, Li X. The prognostic factors for patients with hematological malignancies admitted to the intensive care unit. Springerplus. 2016, 5:2038. 10.1186\/s40064-016-3714-z","journal-title":"Springerplus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06508-w","article-title":"Critically ill cancer patient's resuscitation: a Belgian\/French societies' consensus conference","volume":"47","author":"Meert AP","year":"2021","unstructured":"Meert AP, Wittnebel S, Holbrechts S, et al.. Critically ill cancer patient's resuscitation: a Belgian\/French societies' consensus conference. Intensive Care Med. 2021, 47:1063-1077. 10.1007\/s00134-021-06508-w","journal-title":"Intensive Care Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3320-y","article-title":"Allogeneic stem cell transplantation recipients requiring intensive care: time is of the essence","volume":"97","author":"Orvain C","year":"2018","unstructured":"Orvain C, Beloncle F, Hamel JF, et al.. Allogeneic stem cell transplantation recipients requiring intensive care: time is of the essence. Ann Hematol. 2018, 97:1601-1609. 10.1007\/s00277-018-3320-y","journal-title":"Ann Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087779","article-title":"Long-term health related quality of life following intensive care during treatment for haematological malignancies","volume":"9","author":"van Vliet M","year":"2014","unstructured":"van Vliet M, van den Boogaard M, Donnelly JP, Evers AW, Blijlevens NM, Pickkers P. Long-term health related quality of life following intensive care during treatment for haematological malignancies. PLoS One. 2014, 9:e87779. 10.1371\/journal.pone.0087779","journal-title":"PLoS One"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/417242-bridging-haemato-oncology-and-critical-care-survival-and-functional-outcomes-from-a-portuguese-central-hospital","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T10:46:12Z","timestamp":1764499572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/417242-bridging-haemato-oncology-and-critical-care-survival-and-functional-outcomes-from-a-portuguese-central-hospital"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,30]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.98135","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,30]]}}}